Pages that link to "Q53311439"

The following pages link to Measurement of anti-beta amyloid antibodies in human blood. (Q53311439):

Displaying 23 items.

• Current Research Therapeutic Strategies for Alzheimer's Disease Treatment (Q26765530) (← links)
• A human monoclonal IgG that binds aβ assemblies and diverse amyloids exhibits anti-amyloid activities in vitro and in vivo. (Q34473306) (← links)
• Human anti-Aβ IgGs target conformational epitopes on synthetic dimer assemblies and the AD brain-derived peptide (Q34500145) (← links)
• Amyloid-ß-directed immunotherapy for Alzheimer's disease (Q34548700) (← links)
• A lipoprotein receptor cluster IV mutant preferentially binds amyloid-β and regulates its clearance from the mouse brain (Q34666433) (← links)
• Comparable autoantibody serum levels against amyloid- and inflammation-associated proteins in Parkinson's disease patients and controls (Q35106166) (← links)
• ELISA measurement of specific non-antigen-bound antibodies to Aβ1-42 monomer and soluble oligomers in sera from Alzheimer's disease, mild cognitively impaired, and noncognitively impaired subjects (Q35184148) (← links)
• Anti-aβ oligomer IgG and surface sialic acid in intravenous immunoglobulin: measurement and correlation with clinical outcomes in Alzheimer's disease treatment (Q35590968) (← links)
• Effect of IVIG Formulation on IgG Binding to Self- and Exo- Antigens In Vitro and In Vivo (Q36113220) (← links)
• Effective anti-Alzheimer Aβ therapy involves depletion of specific Aβ oligomer subtypes (Q36894417) (← links)
• Increased Number of Plasma B Cells Producing Autoantibodies Against Aβ42 Protofibrils in Alzheimer's Disease. (Q37044228) (← links)
• Detection of Soluble Amyloid-β Oligomers and Insoluble High-Molecular-Weight Particles in CSF: Development of Methods with Potential for Diagnosis and Therapy Monitoring of Alzheimer's Disease (Q37960496) (← links)
• Alzheimers disease: review of emerging treatment role for intravenous immunoglobulins (Q38122150) (← links)
• Clinical trials of intravenous immunoglobulin for Alzheimer's disease (Q38206711) (← links)
• Should development of Alzheimer's disease-specific intravenous immunoglobulin be considered? (Q38283308) (← links)
• A phase 3 trial of IV immunoglobulin for Alzheimer disease (Q38378475) (← links)
• An Oral Aβ Vaccine Using a Recombinant Adeno-Associated Virus Vector in Aged Monkeys: Reduction in Plaque Amyloid and Increase in Aβ Oligomers (Q40604766) (← links)
• Specific serum antibody binding to phosphorylated and non-phosphorylated tau in non-cognitively impaired, mildly cognitively impaired, and Alzheimer's disease subjects: an exploratory study (Q47099501) (← links)
• Electrochemical Detection of Plasma Immunoglobulin as a Biomarker for Alzheimer's Disease. (Q47139195) (← links)
• Intravenous immunoglobulin for Alzheimer's disease (Q48397446) (← links)
• Overview of immunotherapy in Alzheimer's disease (AD) and mechanisms of IVIG neuroprotection in preclinical models of AD. (Q48585657) (← links)
• The amyloid cascade and Alzheimer's disease therapeutics: theory versus observation (Q91559566) (← links)
• Aβ(M1-40) and Wild-Type Aβ40 Self-Assemble into Oligomers with Distinct Quaternary Structures (Q92816520) (← links)